QUILLIVANT XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QUILLIVANT XR (QUILLIVANT XR).
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
| Metabolism | Primarily metabolized by de-esterification via carboxylesterase 1 (CES1) to ritalinic acid, a major inactive metabolite. Minor pathways include hydroxylation via CYP2D6 to p-hydroxy-methylphenidate, which is further glucuronidated. Methylphenidate is not significantly metabolized by CYP450 enzymes. |
| Excretion | Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%. |
| Half-life | Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours. |
| Protein binding | <10% bound to plasma proteins. |
| Volume of Distribution | 3–4 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Approximately 70% after oral administration. |
| Onset of Action | Oral: ~1-2 hours. |
| Duration of Action | Up to 12 hours due to extended-release delivery. |
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
| Dosage form | FOR SUSPENSION, EXTENDED RELEASE |
| Renal impairment | eGFR 30-89 mL/min: No adjustment needed. eGFR <30 mL/min: Not recommended due to lack of data. |
| Liver impairment | Child-Pugh A: No adjustment needed. Child-Pugh B-C: Not recommended due to lack of data. |
| Pediatric use | Children 6-12 years: Initial 25 mg once daily; may increase to 50 mg after 1 week. Adolescents 13-17 years: Initial 25 mg once daily; may increase to 50 mg after 1 week; maximum 75 mg/day. |
| Geriatric use | Start at low end of dosing range (25 mg once daily) due to increased sensitivity and potential for decreased renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for QUILLIVANT XR (QUILLIVANT XR).
| Breastfeeding | Methylphenidate is excreted into human breast milk. M/P ratio not established; limited data show infant doses of 0.2-0.7% of maternal weight-adjusted dose. Cases of infant irritability and poor weight gain reported. American Academy of Pediatrics recommends use with caution, weighing benefits vs risks. Avoiding breastfeeding during peak drug levels (2-4 hours post-dose) may reduce exposure. |
| Teratogenic Risk | Pregnancy Category C. In animal studies, methylphenidate, the active component, demonstrated teratogenic effects (increased incidence of fetal malformations) at doses approximately 2-3 times the maximum recommended human dose. In first trimester, increased risk of cardiac malformations reported in some human observational studies. Second and third trimester: risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (including irritability, feeding difficulties). Data insufficient to quantify absolute risk. |
■ FDA Black Box Warning
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including QUILLIVANT XR, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
| Serious Effects |
["Hypersensitivity to methylphenidate or any component of the formulation","Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIs","Glaucoma","Motor tics or family history of Tourette's syndrome","Severe anxiety, tension, or agitation"]
| Precautions | ["Serious cardiovascular events: Sudden death, stroke, myocardial infarction; avoid in patients with known structural cardiac abnormalities or serious arrhythmias","Blood pressure and heart rate increases: Monitor regularly","Psychiatric adverse reactions: May exacerbate pre-existing psychosis, mania, or aggression; screen for bipolar disorder prior to treatment","Seizures: Use with caution in patients with a history of seizures","Priapism: Seek immediate medical attention for prolonged erections","Peripheral vasculopathy: Raynaud's phenomenon; monitor for digital changes","Long-term suppression of growth: Monitor height and weight during treatment"] |
Loading safety data…
| Fetal Monitoring | Maternal: Blood pressure and heart rate monitoring at each visit; assess for signs of cardiovascular adverse events. Fetal: Ultrasound to monitor fetal growth and anatomy; consider fetal echocardiography if first trimester exposure. Neonatal: Monitor for withdrawal symptoms (irritability, hypertonia, feeding problems) and growth parameters after delivery. |
| Fertility Effects | In animal studies, methylphenidate did not impair fertility. Human data are limited; however, stimulants may affect reproductive hormones: case reports of irregular menstruation and galactorrhea. No conclusive evidence of reduced fertility. Advise preconception counseling. |